Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. (SNYR) reported a Form 4 showing a stock option grant to Kenek Brands Inc., which is controlled by reporting person Jack Ross, the company's CEO and Chairman. The derivative award is a 750,000-share option with an exercise price of $2.38, recorded on 09/18/2025. The filing states the option vests one-third on the first anniversary of grant and the remaining two-thirds in equal monthly installments over the following 24 months, subject to continued service. The reporting person disclaims direct ownership; the shares are owned directly by Kenek Brands Inc., making Ross an indirect beneficial owner. The Form is signed by counsel on 09/22/2025.
Synergy CHC Corp. (SNYR) reported a Form 4 showing a stock option grant to Kenek Brands Inc., which is controlled by reporting person Jack Ross, the company's CEO and Chairman. The derivative award is a 750,000-share option with an exercise price of $2.38, recorded on 09/18/2025. The filing states the option vests one-third on the first anniversary of grant and the remaining two-thirds in equal monthly installments over the following 24 months, subject to continued service. The reporting person disclaims direct ownership; the shares are owned directly by Kenek Brands Inc., making Ross an indirect beneficial owner. The Form is signed by counsel on 09/22/2025.
Synergy CHC Corp. reported that on September 22, 2025, board member Scott Woodburn resigned from the Board of Directors and all its committees in connection with his new role as the Company’s Head of Strategic Partnerships. The company states that his resignation was not due to any disagreement with the company, its board, or management regarding operations, policies, or practices.
The Board appointed Teresa Thompson to fill the resulting board vacancy and to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. She will receive annual cash compensation of $25,000 and an annual equity award of $25,000 for her board service. Thompson previously served as a pharmacy OTC buyer for Costco Wholesale from September 1986 to June 2025, overseeing U.S. vitamins and supplements, and was appointed for her experience in the vitamin, supplement, and retail markets.
Synergy CHC Corp. reported that on September 22, 2025, board member Scott Woodburn resigned from the Board of Directors and all its committees in connection with his new role as the Company’s Head of Strategic Partnerships. The company states that his resignation was not due to any disagreement with the company, its board, or management regarding operations, policies, or practices.
The Board appointed Teresa Thompson to fill the resulting board vacancy and to serve on the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. She will receive annual cash compensation of $25,000 and an annual equity award of $25,000 for her board service. Thompson previously served as a pharmacy OTC buyer for Costco Wholesale from September 1986 to June 2025, overseeing U.S. vitamins and supplements, and was appointed for her experience in the vitamin, supplement, and retail markets.
Synergy CHC Corp. entered a material underwriting agreement and sold 1,750,000 shares of common stock at $2.50 per share in a public offering, generating gross proceeds of $4.375 million before fees and expenses. Bancroft Capital, LLC acted as representative of the underwriters, who also received a 45-day option to purchase up to 262,500 additional shares to cover over-allotments at the same public price, less underwriting discounts and commissions.
The company plans to use the net proceeds for working capital and other general corporate purposes. It also issued Representative Warrants to Bancroft Capital, LLC and its designees to purchase up to 52,500 shares at an exercise price of $2.75 per share, subject to a 180-day lock-up and 180-day non-exercise period from the pricing date, with expirations staggered over the third, fourth, and fifth anniversaries of the closing date.
Synergy CHC Corp. ("Synergy" or "SNYR") is offering 1,750,000 shares of common stock with associated underwriter warrants and an overallotment option. For the six months ended June 30, 2025, net revenue was $16.3 million, down 6% versus the prior-year period; FOCUSfactor comprised ~86% of revenue while Flat Tummy was ~14%. For the same period Synergy reported net income of $2.3 million and EBITDA of $5.8 million, representing year-over-year changes of +90% and +67%, respectively. Historic FOCUSfactor annual revenue declined from $37.2 million (2023) to $30.8 million (2024). As of June 30, 2025 the company had a working capital surplus of $12.4 million and an as‑adjusted net tangible book value per share after the offering of $(0.71), producing stated immediate dilution to new investors of $3.21 per share.
Synergy CHC Corp. filed a current report to share that it has released a press release about new business developments. The company notes that this press release is furnished as an exhibit under Regulation FD, which is designed to provide fair disclosure of important company information to the market.
The information in this section of the report, including the press release exhibit, is treated as "furnished" rather than "filed" under securities laws, which affects how certain legal liability provisions apply. Synergy CHC Corp.’s common stock trades on The Nasdaq Stock Market LLC under the symbol SNYR.
Synergy CHC Corp. (SNYR) filed an S-1 registration/prospectus describing a proposed public offering and continuing operations centered on two consumer health brands, FOCUSfactor and Flat Tummy. FOCUSfactor accounted for the majority of revenue (86% for the six months ended June 30, 2025; 88% for year ended December 31, 2024) and generated net revenues of $14.0 million for the six months ended June 30, 2025 and $30.7 million for the year ended December 31, 2024 (down from $37.2 million in 2023). For the six months ended June 30, 2025 the company reported net revenues of $16.3 million, net income of $2.3 million, EBITDA of $5.8 million and a working capital surplus of $12.4 million. The prospectus discloses an assumed public offering price of $3.92 per share, a 7% underwriting commission, and Underwriter Warrants exercisable at $4.31 (110% of the assumed price) with staged expirations over three to five years. The company details international expansion plans, manufacturing and distribution arrangements with major retailers, outstanding indebtedness arrangements and potential dilution metrics showing as-adjusted net tangible book value per share would remain negative under the assumed offering.
Synergy CHC Corp. (SNYR) delivered higher profitability in the second quarter of 2025 while executing material debt refinancing. Revenue for the three months ended June 30, 2025 totaled $8,134,996, including $1,400,000 of license revenue, producing gross profit of $6,238,605. Net income after tax was $1,473,237 for the quarter ($2,349,501 for the six months), driving basic and diluted EPS of $0.17 for the quarter and $0.27 for the six months. Total assets were $19,726,346 with cash and restricted cash of $1,558,561. Total liabilities were $32,105,546, and stockholders' deficit improved to $(12,379,200). In May 2025 the company drew a $17.5 million term loan (with a $2.5 million delayed draw) and used proceeds to repay and restructure prior indebtedness, record a $2,154,522 gain on settlement of notes payable, issue pre-funded warrants and shares in partial debt settlements, and record related debt discounts and issuance costs. Management reported a working capital surplus of $12,383,132 and concluded these actions alleviate substantial doubt about the company’s ability to continue as a going concern for the next twelve months.
Synergy CHC Corp. reported that it has released its financial and operating results for the quarter ended June 30, 2025. The company disclosed these results through a press release dated August 14, 2025, which is included as Exhibit 99.1.
The disclosure is made under Item 2.02, which means the information in the press release is being furnished rather than formally filed under certain Exchange Act liability provisions. This 8-K informs investors where to find the full quarterly results while keeping the detailed financial data in the attached press release.
Synergy CHC Corp. (SNYR) | Form 4 filed 07/31/2025
CEO/Chairman Jack Ross reported a series of open-market purchases between 06/11/25 and 07/30/25. In 24 separate transactions he bought 27,900 common shares at weighted-average prices ranging from $2.15-$3.90, spending roughly $80k-$90k and increasing his direct stake to 410,507 shares.
Including indirect holdings through four controlled entities—Rosscor Brands (300,000 sh), Gowan Private Equity (3,679,056 sh), Dunhill Distribution (269,635 sh) and Gowan Capital (136,559 sh)—Ross now beneficially owns ≈4.8 million shares.
No sales or derivative transactions were reported. The repeat buying by a 10% owner and key insider may signal confidence ahead of upcoming catalysts, but dollar amounts are modest relative to total market capitalization.